BioAlliance Pharma Publishes its first Shareholder Newsletter

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announces the publication of its first Shareholder Newsletter (1).

This Newsletter completes BioAlliance Pharma’s communication with all of its shareholders, in addition to its website, its press releases and its participation in the financial community events.

This first issue follows the press release of April 16, 2014, announcing the planned merger between BioAlliance Pharma and Topotarget to create a leading orphan oncology company. Judith Greciet, CEO of BioAlliance Pharma, addresses shareholders to present this merger’s key points: its expected benefits, major assets to drive growth and value, key transaction details and its consequences.

 

(1)    The Shareholder Newsletter is available on the website at: www.onxeo.com (News or Investors).

140429EN_Shareholder Newsletter